Nuwellis reported second quarter 2026 net sales of $2.0 million, a 14% increase year-over-year, with gross margin expanding to 76% from 56%. The company raised approximately $12.7 million in gross proceeds through June and July financing activities, extending its cash runway through the second quarter of 2027. Nuwellis appointed Mike McCormick as President and CEO effective June 30, 2026, and advanced an FDA label expansion for its Aquadex system to patients weighing 5 kilograms or more. The company operates in the medical technology industry, developing solutions for cardiorenal conditions.
